Tartu Linn

• A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended
  2023-503785-22-00 5 2024-03-25 complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
• Vancomycin treatment in critically ill adults using model-informed precision dosing tool – prospective low-intervention clinical trial. (Pro … Ended
  2023-509003-32-00 6 2024-03-01 Serious infections where according to the treating physician's decisio
• Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended
  2023-503790-37-00 5 2024-01-09 Post-Menopausal Osteoporosis
• A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18 … Ended
  2024-510571-37-00 7 2023-12-06 Herpes Simplex
• The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older. Ended
  2023-503763-42-00 5 2023-11-03 Healthy individuals or individuals with stable comorbidities which inc
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 5 2023-09-13 Macular edema secondary to retinal vein occlusion
• To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitis Ended
  2024-511615-16-00 4 2023-08-25 atopic dermatitis
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab) Ended
  2023-505711-20-00 6 2023-08-13 Chronic rhinosinusitis with nasal polyps
• Study to Assess the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of C … Ended
  2024-515463-55-00 5 2023-05-18 Complicated urinary tract infection (cUTI) and acute uncomplicated pye
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• A multi-center study to evaluate the safety, tolerability and efficacy of TIN816 in patients at risk for acute kidney injury following a car … Ended
  2024-511621-64-00 4 2023-01-18 Acute kidney injury
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended
  2024-511263-28-00 6 2022-04-08 Hypercholesterolemia
• A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended
  2024-513304-33-00 5 2022-03-17 Type 1 diabetes mellitus
• Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended
  2023-508820-37-00 5 2022-02-03 Cytomegalovirus Infection (CMV)
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia … Ended
  2024-510744-31-00 5 2021-10-06 Giant cell arteritis (GCA)
• Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis Ended
  2023-509937-37-00 4 2021-07-21 Osteoarthritis
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 5 2021-06-17 Chronic Obstructive Pulmonary Disease (COPD)
• Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER … Ended
  2024-512012-21-00 5 2021-04-08 Chronic Obstructive Pulmonary Disease
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended
  2023-504990-19-00 5 2021-04-06 Agitation in Patients With Dementia of the Alzheimer's Type
• This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use … Ended
  2023-503771-13-00 4 2021-01-28 Classic Congenital Adrenal Hyperplasia
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien … Ended
  2023-507415-35-00 5 2021-01-15 Psoriatic Arthritis
• This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of … Ended
  2023-503770-21-00 4 2021-01-05 Classic Congenital Adrenal Hyperplasia

Showing 97–120 of 127 trials